MG-O-1609

MG-O-1609 is a preclinical-stage small molecule inhibitor being developed by Metagone Biotech (also known as Theratocular Biotek) for the treatment of tumor-agnostic cancers. The drug targets phosphorylated Death-Associated Protein Kinase (pDAPK), a serine/threonine kinase that plays a critical role in regulating cell death pathways, including apoptosis and autophagy. By modulating the pDAPK-related pathway, MG-O-1609 aims to exert anti-tumor effects across a broad range of cancer types, regardless of their tissue of origin. It is part of Metagone's oncology pipeline, which focuses on developing targeted therapies for malignancies with specific molecular drivers.